国产女人香蕉精品视频_国产精品乱人无码伦中文āv一级在线片_AV十八岁在线免费观看_精品成人免费国产_亚洲一区二区三区伊人_两个男生相恋的vlog_香蕉视频下载.apk_日韩一区二区高潮_亚洲日韩欧美内射姐弟_国产亚洲精品A在线观看下载

丹娜法伯癌癥研究院(Dana-Farber Cancer Institute )--甲狀腺癌癥中心 主任

丹娜法伯癌癥研究院(Dana-Farber Cancer Institute )-- 內(nèi)分泌癌癥中心 主任

哈佛醫(yī)學(xué)院助理教授

【專長(zhǎng)領(lǐng)域】

頭頸腫瘤、內(nèi)分泌腫瘤、甲狀腺癌、唾液腺癌、喉癌

【教育背景】

德國(guó)雷根斯堡大學(xué)取得醫(yī)學(xué)博士學(xué)位

雷根斯堡大學(xué)病理科住院醫(yī)師培訓(xùn)

賓夕法尼亞大學(xué)內(nèi)科實(shí)習(xí)及住院醫(yī)師培訓(xùn)

西北大學(xué)血液/腫瘤?？婆嘤?xùn)

【學(xué)術(shù)著作】(摘選)

Sridharan V, Rahman RM, Huang RY, Chau NG, Lorch JH, Uppaluri R, Haddad RI, Hanna GJ, Schoenfeld JD. Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. Oral Oncol. 2018 Oct; 85:29-34.

晚期頭頸部鱗狀細(xì)胞癌免疫檢查點(diǎn)抑制劑治療反應(yīng)的影像學(xué)預(yù)測(cè)指標(biāo)

Groden PJ, Lee TC, Bhattacharyya S, Connors J, Lorch J. Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma. Front Med (Lausanne). 2017; 4:220.

碘難治性轉(zhuǎn)移性乳頭狀甲狀腺癌患者樂(lè)伐替尼相關(guān)的頸動(dòng)脈夾層

Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, Chau NG, Schoenfeld JD, Lorch JH, Uppaluri R, MacConaill LE, Haddad RI. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018 Feb 22; 3(4).

基因移碼可預(yù)測(cè)頭頸癌患者抗PD-1/PD-L1反應(yīng)

Hanna GJ, Woo SB, Li YY, Barletta JA, Hammerman PS, Lorch JH. Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma. Int J Oral Maxillofac Surg. 2018 May; 47(5):568-577.

腫瘤PD-L1表達(dá)與提高年輕女性口腔鱗狀細(xì)胞癌患者生存率和降低復(fù)發(fā)風(fēng)險(xiǎn)相關(guān)

Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD Jr, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, J?nne PA, Lorch JH. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res. 2018 Apr 1;24(7):1546-1553.

侵襲性碘難治性甲狀腺癌對(duì)依維莫司的基因相關(guān)反應(yīng)：一項(xiàng)II期試驗(yàn)

【臨床試驗(yàn)】(摘選)

Nivolumab Plus Ipilimumab in Thyroid Cancer

納武單抗聯(lián)合伊匹單抗免疫療法治療甲狀腺癌

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

以瑞戈非尼為二線或三線治療轉(zhuǎn)移性甲狀腺髓樣癌的研究

A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer

MLN0128在轉(zhuǎn)移性未分化型甲狀腺癌的二期研究

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

碘難治性甲狀腺癌應(yīng)用依維莫司

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Bevacizumab/Tarceva和Tarceva/Sulindac在頭頸部鱗狀細(xì)胞癌中的應(yīng)用